Related Experiment Video
Updated: Sep 13, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
BioAug-Net: a bioimage sensor-driven attention-augmented segmentation framework with physiological coupling for early
Muhammad Arshad1, Chengliang Wang2, Muhammad Wajeeh Us Sima1
1Department of Computer Science and Technology, College of Computer Science, Chongqing University, Chongqing, 400044, China.
None:
Accurate segmentation of the prostate peripheral zone (PZ) in T2-weighted MRI is critical for the early detection of prostate cancer. Existing segmentation methods are hindered by significant inter-observer variability (37.4 ± 5.6%), poor boundary localization, and the presence of motion artifacts, along with challenges in clinical integration. In this study, we propose BioAug-Net, a novel framework that integrates real-time physiological signal feedback with MRI data, leveraging transformer-based attention mechanisms and a probabilistic clinical decision support system (PCDSS). BioAug-Net features a dual-branch asymmetric attention mechanism: one branch processes spatial MRI features, while the other incorporates temporal sensor signals through a BiGRU-driven adaptive masking module. Additionally, a Markov Decision Process-based PCDSS maps segmentation outputs to clinical PI-RADS scores, with uncertainty quantification. We validated BioAug-Net on a multi-institutional dataset (n=1,542) and demonstrated state-of-the-art performance, achieving a Dice Similarity Coefficient of 89.7% (p < 0.001), sensitivity of 91.2% (p < 0.001), specificity of 88.4% (p < 0.001), and HD95 of 2.14 mm (p < 0.001), outperforming U-Net, Attention U-Net, and TransUNet. Sensor integration improved segmentation accuracy by 12.6% (p < 0.001) and reduced inter-observer variation by 48.3% (p < 0.001). Radiologist evaluations (n=3) confirmed a 15.0% reduction in diagnosis time (p = 0.003) and an increase in inter-reader agreement from K = 0.68 to K = 0.82 (p = 0.001). Our results show that BioAug-Net offers a clinically viable solution for early prostate cancer detection through enhanced physiological coupling and explainable AI diagnostics.

